ID27487A - Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat - Google Patents
Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetatInfo
- Publication number
- ID27487A ID27487A IDW20001981A ID20001981A ID27487A ID 27487 A ID27487 A ID 27487A ID W20001981 A IDW20001981 A ID W20001981A ID 20001981 A ID20001981 A ID 20001981A ID 27487 A ID27487 A ID 27487A
- Authority
- ID
- Indonesia
- Prior art keywords
- dioxoethyl
- phenylmethyl
- indol
- acetate
- ethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7665998P | 1998-03-03 | 1998-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ID27487A true ID27487A (id) | 2001-04-12 |
Family
ID=22133426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IDW20001981A ID27487A (id) | 1998-03-03 | 1999-03-02 | Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat |
Country Status (21)
Country | Link |
---|---|
US (1) | US6166062A (zh) |
EP (1) | EP1058547B1 (zh) |
JP (3) | JP2002505282A (zh) |
KR (1) | KR20010034552A (zh) |
CN (1) | CN1299277A (zh) |
AT (1) | ATE310513T1 (zh) |
AU (1) | AU757002B2 (zh) |
BR (1) | BR9908479A (zh) |
CA (1) | CA2322796A1 (zh) |
DE (1) | DE69928500T2 (zh) |
EA (1) | EA003864B1 (zh) |
ES (1) | ES2253877T3 (zh) |
HU (1) | HUP0102812A3 (zh) |
ID (1) | ID27487A (zh) |
IL (1) | IL138154A0 (zh) |
NO (1) | NO20004306L (zh) |
NZ (1) | NZ506578A (zh) |
PL (1) | PL342822A1 (zh) |
TR (1) | TR200002543T2 (zh) |
TW (1) | TW570795B (zh) |
WO (1) | WO1999044604A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001236440A1 (en) * | 2000-01-25 | 2001-08-07 | Eli Lilly And Company | Method for the treatment of inflammation with spla2 inhibitors |
JP2003525901A (ja) * | 2000-03-09 | 2003-09-02 | イーライ・リリー・アンド・カンパニー | sPLA2インヒビターによる腎臓機能障害の治療方法 |
EP1303262A2 (en) * | 2000-07-14 | 2003-04-23 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
TWI232102B (en) * | 2001-07-17 | 2005-05-11 | Shionogi & Co | A pharmaceutical formulation for injection |
CN1568999A (zh) | 2003-07-14 | 2005-01-26 | 南宁枫叶药业有限公司 | 稳定的医药用河豚毒素冷冻干燥制剂 |
EP1742535A4 (en) * | 2004-05-06 | 2008-10-15 | Cydex Pharmaceuticals Inc | MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN |
PT2029134E (pt) * | 2006-06-09 | 2011-11-02 | Ucb Pharma Gmbh | Composições farmacêuticas estabilizadas compreendendo fesoterodina |
WO2008100235A2 (fr) * | 2007-02-12 | 2008-08-21 | Medis Lab | Le sucralose solution sterile sans conservateurs |
JP5174365B2 (ja) * | 2007-03-23 | 2013-04-03 | 第一三共株式会社 | キノロン含有凍結乾燥製剤の製造方法 |
EP2106788A1 (en) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Liquid and freeze dried formulations |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
KR20140053952A (ko) * | 2011-08-26 | 2014-05-08 | 제이더블유중외제약 주식회사 | 피라지노-트리아진 유도체를 포함하는 조성물 |
EP2923710A1 (en) | 2014-03-27 | 2015-09-30 | Universitätsklinikum Heidelberg | Bacterial phospholipase inhibitors as modulator of colonic bacterial flora |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO873860L (no) * | 1986-10-31 | 1988-05-02 | Asta Pharma Ag | Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling. |
JPH02207092A (ja) * | 1989-02-07 | 1990-08-16 | Kirin Brewery Co Ltd | アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法 |
ES2142409T3 (es) * | 1993-10-27 | 2000-04-16 | Upjohn Co | Prostaglandina e 1 estabilizada. |
KR100368707B1 (ko) * | 1994-04-01 | 2003-06-02 | 일라이 릴리 앤드 캄파니 | 1H-인돌-3-글리옥실아미드sPLA2억제제 |
-
1999
- 1999-03-02 ES ES99908612T patent/ES2253877T3/es not_active Expired - Lifetime
- 1999-03-02 CA CA002322796A patent/CA2322796A1/en not_active Abandoned
- 1999-03-02 EA EA200000897A patent/EA003864B1/ru not_active IP Right Cessation
- 1999-03-02 DE DE69928500T patent/DE69928500T2/de not_active Expired - Lifetime
- 1999-03-02 AT AT99908612T patent/ATE310513T1/de not_active IP Right Cessation
- 1999-03-02 KR KR1020007009726A patent/KR20010034552A/ko not_active Application Discontinuation
- 1999-03-02 NZ NZ506578A patent/NZ506578A/en unknown
- 1999-03-02 EP EP99908612A patent/EP1058547B1/en not_active Expired - Lifetime
- 1999-03-02 BR BR9908479-1A patent/BR9908479A/pt not_active IP Right Cessation
- 1999-03-02 AU AU27998/99A patent/AU757002B2/en not_active Ceased
- 1999-03-02 IL IL13815499A patent/IL138154A0/xx unknown
- 1999-03-02 WO PCT/US1999/004516 patent/WO1999044604A1/en active IP Right Grant
- 1999-03-02 HU HU0102812A patent/HUP0102812A3/hu unknown
- 1999-03-02 PL PL99342822A patent/PL342822A1/xx not_active Application Discontinuation
- 1999-03-02 TR TR2000/02543T patent/TR200002543T2/xx unknown
- 1999-03-02 CN CN99805662A patent/CN1299277A/zh active Pending
- 1999-03-02 ID IDW20001981A patent/ID27487A/id unknown
- 1999-03-02 US US09/260,490 patent/US6166062A/en not_active Expired - Lifetime
- 1999-03-02 JP JP2000534206A patent/JP2002505282A/ja active Pending
- 1999-08-27 TW TW088103212A patent/TW570795B/zh active
-
2000
- 2000-08-29 NO NO20004306A patent/NO20004306L/no not_active Application Discontinuation
-
2005
- 2005-11-16 JP JP2005330964A patent/JP2006096761A/ja not_active Withdrawn
-
2010
- 2010-11-05 JP JP2010247975A patent/JP2011021042A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
DE69928500D1 (de) | 2005-12-29 |
NZ506578A (en) | 2003-09-26 |
ES2253877T3 (es) | 2006-06-01 |
JP2006096761A (ja) | 2006-04-13 |
US6166062A (en) | 2000-12-26 |
PL342822A1 (en) | 2001-07-02 |
CN1299277A (zh) | 2001-06-13 |
BR9908479A (pt) | 2000-12-05 |
AU757002B2 (en) | 2003-01-30 |
ATE310513T1 (de) | 2005-12-15 |
WO1999044604A9 (en) | 2000-01-20 |
EA200000897A1 (ru) | 2001-02-26 |
HUP0102812A3 (en) | 2002-01-28 |
JP2011021042A (ja) | 2011-02-03 |
CA2322796A1 (en) | 1999-09-10 |
AU2799899A (en) | 1999-09-20 |
EP1058547B1 (en) | 2005-11-23 |
TR200002543T2 (tr) | 2000-11-21 |
WO1999044604A1 (en) | 1999-09-10 |
JP2002505282A (ja) | 2002-02-19 |
EP1058547A1 (en) | 2000-12-13 |
NO20004306L (no) | 2000-10-10 |
IL138154A0 (en) | 2001-10-31 |
DE69928500T2 (de) | 2006-08-03 |
NO20004306D0 (no) | 2000-08-29 |
TW570795B (en) | 2004-01-11 |
HUP0102812A2 (hu) | 2001-12-28 |
EA003864B1 (ru) | 2003-10-30 |
KR20010034552A (ko) | 2001-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ID27487A (id) | Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat | |
TR199800436A2 (xx) | Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�. | |
EA200000871A1 (ru) | Ингибиторы фосфолипазных ферментов | |
BR0014486A (pt) | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado | |
BR0016555A (pt) | Composições farmacêuticas que proporcionam concentrações acrescidas de droga | |
HUP0300850A2 (hu) | Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
IL208697A0 (en) | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol | |
ATE404176T1 (de) | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors | |
TR200000132T2 (tr) | Dolastatin 15 türevleri | |
DK0722313T3 (da) | Viskoelastiske sammensætninger af fluorerede organiske forbindelser | |
TR199802394A2 (xx) | Proteinleri stabilize etmek i�in geli�tirilmi� proses. | |
GEP20115348B (en) | Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants) | |
AR006523A1 (es) | Compuestos ciclicos, inhibidores de la adhesion | |
ES2187820T3 (es) | Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida. | |
BRPI0407652A (pt) | método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição | |
TR200201103T2 (tr) | İkame edilmiş benzimidazol formülasyonları | |
JP2945923B2 (ja) | 養毛剤 | |
PT769951E (pt) | Composicao de oxitetraciclina de longa accao | |
TR200100611T2 (tr) | İbuprofen ve domperidon içeren farmasötik kompozisyonlar | |
BR0009214A (pt) | Composições aquosas estáveis contendo umcomposto de silìcio | |
BR0113783A (pt) | Composição aquosa e métodos para aumentar a eficácia de uma composição contendo enzimas e para limpar um instrumento médico | |
ID21755A (id) | Antijamur azol yang mengandung ester asam amino | |
FR2740973A1 (fr) | Nouvelle forme d'administration de l'hydroxocobalamine et son utilisation dans les intoxications par les cyanures | |
EA200900249A1 (ru) | Фармацевтическая композиция и способ ее получения | |
TR200003570T2 (tr) | Mumbaistatin, Üretim yöntemi ve farmasötik kullanımı |